english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Drugs in 2021: a brief review

Just 17 of the 108 new marketing authorisations analysed and rated in our French edition in 2021 represented a major or notable therapeutic advance for patients. How does this finding for 2021 compare with prior years?
1 April 2022

Fentanyl: overdose and dependence with fast-acting forms

Fast-acting forms of fentanyl, a strong opioid analgesic, must be used with caution, patients must be thoroughly informed, and excessive doses must be avoided.
1 April 2022

Isotretinoin: too many pregnancies still at risk

Despite a series of measures, unborn children are still being exposed to isotretinoin during pregnancy, with a risk of serious malformations and/or neuropsychiatric disorders.
1 April 2022

Down with the "p value"! A move to democratise health information

1 April 2022

• Down with the decline in vigilance! Mind your p's and q's

In today's ever more skewed world, it's more important than ever to use every tool at one's disposal to determine if a result is significant. Or just plain old fishy.
1 April 2022

Watch the video of the webinar "Prescrire, A Critical Eye on New Drugs"

 VIDEO  How many new drugs offer an advantage and how many bring nothing new? Prescrire has been answering this key question since 1981. In a March 2022 webinar organised by Consilium Scientific, Pierre Chirac of Prescrire explained the reason for Prescrire's existence, the people behind it, its operations, its main achievements, and its limitations.
21 March 2022

Ivacaftor + tezacaftor + elexacaftor (Kaftrio°) in cystic fibrosis with at least one F508del mutation: respiratory symptoms alleviated in the short term

FEATURED REVIEW Is this triple therapy more effective than dual therapy at reducing the incidence of pulmonary exacerbations and alleviating symptoms? Does it slow disease progression and extend survival? What adverse effects are associated with the addition of elexacaftor?
Full review (4 pages) available for download by subscribers.
1 March 2022

In the March issue of Prescrire International: Revision of European pharmaceuticals legislation

FREE DOWNLOAD Prescrire has responded to a public consultation on a planned revision of Directive 2001/83 "on the Community code relating to medicinal products" and Regulation 726/2004 "laying down Community procedures for the authorisation and supervision of medicinal products (...) and establishing a European Medicines Agency".
Full text available for free download.
1 March 2022

Rational deprescribing

 Editorial  The term "deprescribing" has been used more and more in recent years. But deprescribing, like prescribing, is not without risk.
1 March 2022

The Prescrire Awards for 2021: two "Pilule d'Or" Awards, and 5 drugs on the "Honours List". Details in the March issue of Prescrire International

ThePrescrire Awards independent French medical journal Prescrire conferred two "Pilule d'Or" ("Golden Pill") Awards for 2021; 5 drugs made the "Honours List", and 2 drugs were deemed "Noteworthy". Details for the Drug and Information Awards, published in the March issue of Prescrire International, are available HERE.
1 March 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90